Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter ended March 31, 2026.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanofi Consumer Healthcare India reported strong Q4 FY26 results with revenue from operations at ₹2,292 million, up 32.8% from ₹1,726 million in Q4 FY25. Profit after tax grew 35.6% to ₹678 million from ₹500 million in the same period last year. Basic EPS for the quarter stood at ₹29.44. Domestic sales grew 15.5% aided by the relaunch of products (Combiflam Suspension, Allegra Suspension, and Depura Kids) following a voluntary recall in 2024. Export sales surged 144.4% on a lower base. Statutory auditors issued an unmodified (clean) limited review report.
Strong double-digit revenue and profit growth indicates healthy business recovery post product recall. The clean audit opinion and robust margins are positive signals for shareholders.